CG Oncology (NASDAQ: CGON) director sells 5,000 shares, exercises options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CG Oncology director Leonard E. Post reported coordinated stock transactions. On June 24, 2026, he sold 5,000 shares of Common Stock in an open-market transaction at $70.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026.
On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per share. After these moves, he directly owned 5,000 common shares and held 106,077 director stock options expiring on July 8, 2028, indicating an exercise-and-sell pattern with a substantial remaining option position.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 5,000 shares ($350,000)
Net Sell
3 txns
Insider
POST LEONARD E
Role
null
Sold
5,000 shs ($350K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $0.60 | $3K |
| Sale | Common Stock | 5,000 | $70.00 | $350K |
Holdings After Transaction:
Director Stock Option (right to buy) — 106,077 shares (Direct, null);
Common Stock — 5,000 shares (Direct, null)
Footnotes (1)
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. Fully vested
Key Figures
Shares sold: 5,000 shares
Sale price: $70.00 per share
Shares exercised: 5,000 shares
+4 more
7 metrics
Shares sold
5,000 shares
Common Stock sold in open market on June 24, 2026
Sale price
$70.00 per share
Price for 5,000 Common Stock shares sold
Shares exercised
5,000 shares
Common shares acquired via option exercise on June 24, 2026
Option exercise price
$0.60 per share
Director stock option exercise price for 5,000 shares
Shares owned after
5,000 shares
Common Stock directly owned following reported transactions
Options remaining
106,077 options
Director stock options outstanding after exercise
Option expiration
July 8, 2028
Expiration date for remaining director stock options
Key Terms
Rule 10b5-1 trading plan, open-market sale, Director Stock Option (right to buy), derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Director Stock Option (right to buy) financial
"security_title": "Director Stock Option (right to buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transactions did CG Oncology (CGON) report for Leonard E. Post?
CG Oncology director Leonard E. Post sold 5,000 common shares and exercised options for 5,000 shares on June 24, 2026. These coordinated transactions combined an open-market sale with an option exercise at a low strike price.
Did Leonard E. Post exercise stock options in this CGON Form 4 filing?
Yes. Leonard E. Post exercised a director stock option covering 5,000 underlying CG Oncology common shares at a $0.60 exercise price. This exercise converted derivative rights into shares on the same date as the reported sale.
What CGON equity position does Leonard E. Post hold after these transactions?
After the June 24, 2026 transactions, Leonard E. Post directly owned 5,000 CG Oncology common shares and held 106,077 director stock options. The options relate to common stock and are scheduled to expire on July 8, 2028.
What is the expiration date of Leonard E. Post’s CGON director stock options?
The director stock options reported for Leonard E. Post expire on July 8, 2028. Following the June 24, 2026 exercise of 5,000 option shares, he retained 106,077 director stock options with that stated expiration date.